Recent 8-K filings for NTRB

• June 22, 2026, 8:02 AM ET debt materiality 0.55 neutral item 1.01item 9.01 ◈ Material Agreements

  Nutriband enters amended $5M credit line at 7% interest for AVERSA Fentanyl

  $5M credit line facility amended as of June 1, 2026, replacing prior $5M facility expiring July 2026.

• April 7, 2026, 7:59 PM ET other material materiality 0.65 positive item 7.01item 9.01

  Nutriband selects brand name for abuse-deterrent fentanyl patch; will submit to FDA

  Selected commercial worldwide brand name candidate for lead product, a fentanyl transdermal system with abuse-deterrent technology.

• February 13, 2026, 6:59 PM ET other material materiality 0.70 negative item 7.01item 9.01

  Nutriband terminates sale of Pocono Pharmaceuticals to Earth Vision Bio due to buyer default

  Board approved immediate termination of Pocono Pharmaceuticals sale to Earth Vision Bio Inc.

• February 3, 2026, 6:59 PM ET other material materiality 0.15 neutral item 5.07item 9.01

  Nutriband shareholders approve preferred share increase from 10M to 20M; two new directors appointed

  Shareholders approved amendment to increase authorized preferred shares from 10,000,000 to 20,000,000 with 86.25% of votes cast in favor.

• December 30, 2025, 6:59 PM ET M&A materiality 0.75 positive item 7.01item 9.01

  Nutriband sells 90% stake in Pocono Pharma for $5M to EarthVision Bio; retains 10%

  Agreement to sell 90% interest in subsidiary Pocono Pharmaceutical for $5M USD to EarthVision Bio.

• October 28, 2025, 7:59 PM ET regulatory materiality 0.75 positive item 7.01item 9.01

  Nutriband receives FDA feedback on AVERSA FENTANYL CMC plans; regulatory pathway confirmed as 505(b)(2)

  FDA meeting held September 18, 2025; final minutes received; feedback on CMC, registration batch, and stability plans.

• September 3, 2025, 7:59 PM ET other material materiality 0.30 neutral item 7.01item 9.01

  Nutriband discloses option/warrant exercises from Feb-Jul 2025 totaling 845K shares

  Stock options exercised on 20,055 shares for $44,206 total exercise price.

• August 7, 2025, 7:59 PM ET other material materiality 0.55 neutral item 3.02item 5.03item 9.01 ◈ Governance Changes

  Nutriband issues Series A Preferred stock dividend of 3,008,643 shares to common holders

  Stock dividend of Series A Preferred Stock: 1 share for every 4 common shares, issued Aug 5, 2025.

• July 16, 2025, 7:59 PM ET dividend materiality 0.55 neutral item 5.03item 9.01 ◈ Governance Changes

  Nutriband declares Series A Convertible Preferred stock dividend; record date July 25, 2025

  Board authorized 2,788,678 shares of Series A Convertible Preferred Stock (non-voting).

• April 9, 2025, 7:59 PM ET other material materiality 0.20 neutral item 7.01item 9.01

  Nutriband signs Associate Partnership with MLS team Charlotte FC

  Agreement with Charlotte FC (Major League Soccer) to build brand visibility.

• February 13, 2025, 6:59 PM ET other material materiality 0.60 positive item 7.01item 9.01

  Nutriband formalizes exclusive Aversa Fentanyl partnership with Kindeva; potential $80-200M US sales

  Signed addendum formalizing exclusive development partnership for Aversa Fentanyl with Kindeva Drug Delivery.

• February 12, 2025, 6:59 PM ET other material materiality 0.65 positive item 7.01item 9.01

  Nutriband receives USPTO Notice of Allowance for Aversa abuse deterrent patent

  Notice of Allowance received Feb 3, 2025 for patent app 18/369,241 covering Aversa abuse deterrent transdermal systems.

• January 29, 2025, 6:59 PM ET other material materiality 0.15 neutral item 5.07

  Nutriband stockholders elect directors, approve auditor and stock plan at 2025 annual meeting

  All seven director nominees elected with ~99% of votes cast; each received over 7.4M for votes.

• December 30, 2024, 6:59 PM ET regulatory materiality 0.50 positive item 7.01item 9.01

  Nutriband extends AVERSA patent to Macao; now covered in 46 countries

  Macao IP Office assigned patent number J/9010 with entry date December 17, 2024.

• October 31, 2024, 7:59 PM ET regulatory materiality 0.55 positive item 7.01item 9.01

  Nutriband receives Chinese patent for AVERSA abuse-deterrent transdermal system

  CNIPA fully issued Patent No. ZL 202211158031 for 'Abuse and Misuse Deterrent Transdermal System' related to AVERSA technology.

• September 18, 2024, 7:59 PM ET other material materiality 0.65 positive item 7.01item 9.01

  Nutriband announces $1 million share repurchase program; reaffirms AVERSA Fentanyl NDA timeline

  Share buyback program authorizes repurchase of up to $1,000,000 of common stock.

• June 3, 2024, 7:59 PM ET other materiality 0.20 neutral item 3.02item 9.01

  Nutriband amends 8-K to disclose warrants omitted from prior conversion filing

  Amendment adds 152,460 warrants to purchase common stock at $6.43 per share, expiring May 14, 2029.

• May 21, 2024, 7:59 PM ET other material materiality 0.45 neutral item 3.02item 9.01

  Nutriband converts $300K debt into 76,230 shares at $4.00 per share

  Converted $300,000 principal plus $4,921.79 accrued interest on a Creditline Promissory Note.

• May 17, 2024, 7:59 PM ET leadership materiality 0.30 neutral item 5.02 ◈ executive_change

  Nutriband appoints Sergei Glinka as director effective May 15, 2024

  Appointed Sergei Glinka as a director effective May 15, 2024.

• April 23, 2024, 7:59 PM ET other material materiality 0.70 neutral item 1.01item 9.01 ◈ Material Agreements

  Nutriband raises $8.4M in Regulation S equity offering of units with warrants

  Offered 2.1M units at $4.00 each, each unit comprising one common share and warrant to buy two shares.

• March 28, 2024, 7:59 PM ET leadership materiality 0.50 neutral item 3.02item 8.01item 9.01

  Nutriband grants stock options to CEO, President, CFO, COO, CSO and amends stock plan

  Item 3.02: Unregistered sales of options to purchase 97,500 shares each to CEO Gareth Sheridan and President Serguei Melnik at $2.61/share.

• January 25, 2024, 6:59 PM ET other material materiality 0.15 neutral item 5.07 ◈ Shareholder Votes ×4

  Nutriband stockholders elect six directors, ratify auditor, approve say on pay, choose 1-year frequency

  All six director nominees elected: Sheridan, Melnik, Hamilton, Bujoreanu, Mancas, Gram each with >5.2M votes for.

• January 11, 2024, 6:59 PM ET other material materiality 0.80 positive item 7.01item 9.01

  Nutriband signs commercial development & clinical supply agreement with Kindeva for Aversa Fentanyl patch

  Kindeva to perform commercial process development & supply clinical materials for FDA abuse liability study.

• December 29, 2023, 6:59 PM ET other material materiality 0.55 neutral item 3.02item 9.01

  Nutriband converts $2M note into 1.03M shares at $2.00/share

  Holder TII Jet Services LDA converted $2M principal plus $53,440 accrued interest into 1,026,720 common shares at $2.00/share.

• July 14, 2023, 7:59 PM ET debt materiality 0.65 neutral item 1.01item 9.01 ◈ Material Agreements

  Nutriband replaces $2M credit line with $5M facility at 7% for AVERSA Fentanyl

  Secured $5M credit line at 7% interest, maturing July 13, 2026, replacing prior $2M facility.

• June 21, 2023, 7:59 PM ET other material materiality 0.20 neutral item 7.01

  Nutriband terminates dual listing on MERJ Upstream effective May 31, 2023

  Only one shareholder listed 250,000 shares on Upstream; those shares transferred back to transfer agent.

• March 29, 2023, 7:59 PM ET debt materiality 0.65 positive item 7.01item 9.01

  Nutriband secures $2M credit line for AVERSA Fentanyl commercialization

  Three-year $2,000,000 credit line at 7% interest, non-convertible to common stock.

• January 5, 2023, 6:59 PM ET other material materiality 0.30 neutral item 7.01item 9.01

  Nutriband dual-lists on Upstream trading platform under ticker NTRB

  Common stock (NTRB) begins trading on Upstream on Jan 5, 2023 at 10:00am EST.

• December 30, 2022, 6:59 PM ET other material materiality 0.20 neutral item 3.02item 5.02item 5.07 ◈ Shareholder Votes ×2

  Nutriband grants stock options to directors/officers; annual meeting re-elects all six directors and ratifies auditor

  On Dec 9, 2022, board approved stock options totaling 107,500 shares to seven directors and officers at exercise prices of $3.53 or $3.88.

• October 6, 2022, 7:59 PM ET other material materiality 0.35 positive item 7.01item 9.01

  Nutriband files to dual-list common stock on Upstream digital securities platform

  Application submitted to dual list NTRB shares on Upstream, a trading app for digital securities and NFTs.

• August 19, 2022, 7:59 PM ET other material materiality 0.50 neutral item 3.02item 5.02

  Nutriband grants stock options to CEO, Chairman, CFO, and other officers totaling ~137K shares

  CEO Gareth Sheridan receives 29,167 options at $4.50; Chairman Serguei Melnik 29,167 at $4.50; CFO Gerald Goodman 23,333 at $4.09.

• August 10, 2022, 7:59 PM ET other material materiality 0.40 neutral item 5.03item 7.01item 9.01

  Nutriband announces 7:6 forward stock split; effective August 12, 2022

  7:6 forward stock split; each shareholder gets one additional share for every six held as of August 15 record date.

• August 1, 2022, 7:59 PM ET regulatory materiality 0.55 positive item 7.01item 9.01

  Nutriband receives Canadian patent allowance for AVERSA abuse deterrent transdermal technology

  Canadian Intellectual Property Office issued Notice of Allowance for patent CA 2937649 covering AVERSA transdermal abuse deterrent technology.

• July 27, 2022, 7:59 PM ET other material materiality 0.30 positive item 7.01item 9.01

  Nutriband announces 7:6 forward stock split effective August 15, 2022

  Board declares 7:6 forward split of common stock, effective at 12:01AM on August 15, 2022.

• July 26, 2022, 7:59 PM ET other material materiality 0.65 positive item 7.01item 9.01

  Nutriband cancels 1.2M shares (~15% of outstanding) after final court judgment rescinding 2017 acquisition

  Final Judgment permits cancellation of 1,200,000 shares issued in 2017 for rescinded Advanced Health Brands deal.

• July 15, 2022, 7:59 PM ET litigation materiality 0.70 positive item 7.01item 9.01

  Nutriband wins court verdict to rescind 2017 acquisition and recover 1.2M shares (~15% of outstanding)

  Circuit Court in Orange County, Florida ruled in favor of Nutriband on all issues, rescinding the Advanced Health Brands acquisition.

• January 31, 2022, 6:59 PM ET other material materiality 0.65 positive item 7.01item 9.01

  Nutriband receives US patent for AVERSA abuse deterrent transdermal technology

  USPTO issued patent for 'Abuse and Misuse Deterrent Transdermal System' covering AVERSA platform.

• January 27, 2022, 6:59 PM ET other material materiality 0.70 positive item 5.02item 5.03item 5.07item 7.01item 9.01 ◈ executive_change ×2

  Nutriband expands AVERSA abuse-deterrent pipeline to include buprenorphine and methylphenidate

  Adds AVERSA buprenorphine and AVERSA methylphenidate (ADHD) to pipeline; lead product AVERSA Fentanyl has $80-200M potential US sales.

• January 10, 2022, 6:59 PM ET other material materiality 0.60 positive item 7.01item 9.01

  Nutriband signs feasibility agreement with Kindeva to develop abuse deterrent fentanyl patch AVERSA

  Agreement combines Nutriband's AVERSA abuse deterrent technology with Kindeva's FDA-approved fentanyl patch.

• January 3, 2022, 6:59 PM ET other material materiality 0.40 positive item 7.01item 9.01

  Nutriband receives Korean patent for abuse-deterrent transdermal system AVERSA

  Korean Intellectual Property Office issued full patent titled 'Abuse and Misuse Deterrent Transdermal System'.

• December 30, 2021, 6:59 PM ET other material materiality 0.45 positive item 7.01item 9.01

  Nutriband announces $1M share repurchase program

  Share repurchase program authorized to buy back up to $1,000,000 of common stock.

• October 12, 2021, 7:59 PM ET other material materiality 0.65 positive item 1.01item 9.01

  Nutriband signs exclusive manufacturing deal for COVID-19 antibody monitoring patch

  Exclusive manufacturing agreement via subsidiary Active Intelligence, LLC with Diomics for Diocheck™ patch.

• October 8, 2021, 7:59 PM ET other material materiality 0.75 positive item 3.02item 8.01item 5.02 ◈ executive_change

  Nutriband completes IPO on Nasdaq, nets $5.8M; elects Serguei Melnik as President

  IPO of 1,056,000 units at $6.25/unit, each unit = 1 share + 1 warrant; underwriters' option exercised for 158,400 warrants.

• October 1, 2021, 7:59 PM ET other material materiality 0.65 positive item 8.01

  Nutriband receives USPTO Notice of Allowance for abuse-deterrent transdermal patent

  USPTO allowed patent application 16/707,547 on Sept 27, 2021.

• September 1, 2021, 7:59 PM ET debt materiality 0.55 neutral item 1.01item 9.01

  Nutriband extends $1.5M note maturity to Sept 30, 2021; delays listing deadline

  Amended $1.5M promissory note due date from Aug 31, 2021 to Sept 30, 2021.

Executive changes

Materiality & sentiment trend

Max materiality 0.80 · Median 0.55 · Most common event other_material

23 positive 1 negative 21 neutral

source · NTRB on sec.gov